4:12 PM ET
8-K
Clinical Trial Data
Arcturus Therapeutics Holdings Clinical Trial Data
Arcturus Therapeutics released Phase 2 clinical data for ARCT-810, its mRNA-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency. The company also provided a strategic update on its broader mRNA delivery platform and technology pipeline.